AR006890A1 - Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos - Google Patents

Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos

Info

Publication number
AR006890A1
AR006890A1 ARP970101749A ARP970101749A AR006890A1 AR 006890 A1 AR006890 A1 AR 006890A1 AR P970101749 A ARP970101749 A AR P970101749A AR P970101749 A ARP970101749 A AR P970101749A AR 006890 A1 AR006890 A1 AR 006890A1
Authority
AR
Argentina
Prior art keywords
alkyl
silyl
esters
same
hydrogen
Prior art date
Application number
ARP970101749A
Other languages
English (en)
Original Assignee
Hoechst Marion Roussell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussell Inc filed Critical Hoechst Marion Roussell Inc
Publication of AR006890A1 publication Critical patent/AR006890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los alquil-4-silil-fenoles y ésteres de los mismos como agentes antiateroscleróticos tienen la fórmula (I), donde R1 y R6 son cada unoindependientemente alquilo C1-C6; R2, R3 y R4 son cada uno independientemente hidrógeno o alquilo C1-C6; R es hidrógeno o -C(O)-(CH2)m-Q, donde Q eshidrógeno o -COOH y m es un entero 1, 2, 3 o 4; Z es tio, oxi o un grupo metileno; A es un grupo alquileno C1-C4; R5 y R7 son cada unoindependientemente un alquilo C1-C6 o -(CH2)n-(Ar) donde n es un entero 0, 1, 2 o 3; y Ar es fenilo o naftilo sin sustituir o sustituido con uno a tressustituyentes seleccionados del grupo formado por hidroxi, metoxi, etoxi, halógeno, trifluormetilo, alquilo C1-C6, o -NR8R9, donde R8 y R9 son cada unoindependientemente hidrógeno o alquilo C1-C6; con la condición de que cuando R2 y al menos uno de R5 o R7 es alquilo C1-C6, y Ar no está sustituido contrifluormetilo o -NR8R9, entonces R sea -C(O)-(CH2)m-Q; y pueden ser una sal farmacéuticamente aceptable de los mismos.
ARP970101749A 1996-04-30 1997-04-29 Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos AR006890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/637,968 US5608095A (en) 1996-04-30 1996-04-30 Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents

Publications (1)

Publication Number Publication Date
AR006890A1 true AR006890A1 (es) 1999-09-29

Family

ID=24558107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101749A AR006890A1 (es) 1996-04-30 1997-04-29 Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos

Country Status (19)

Country Link
US (1) US5608095A (es)
EP (1) EP0900225B1 (es)
JP (1) JP4309473B2 (es)
KR (1) KR100503181B1 (es)
CN (1) CN1216993A (es)
AR (1) AR006890A1 (es)
AT (1) ATE212639T1 (es)
AU (1) AU711322B2 (es)
BR (1) BR9709190A (es)
CA (1) CA2251991C (es)
DE (1) DE69710191T2 (es)
DK (1) DK0900225T3 (es)
ES (1) ES2167716T3 (es)
IL (1) IL126758A0 (es)
NO (1) NO985039L (es)
PT (1) PT900225E (es)
TW (1) TW474940B (es)
WO (1) WO1997041129A1 (es)
ZA (1) ZA973503B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
CN1216921A (zh) * 1996-04-30 1999-05-19 赫彻斯特马里恩鲁斯公司 用2,6－二烷基－4－甲硅烷基－苯酚诱导血管细胞粘着分子－1和治疗慢性炎症疾病的方法
DE69829966T2 (de) 1997-05-14 2006-02-09 Atherogenics, Inc. Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
JP2002506443A (ja) * 1997-06-25 2002-02-26 アベンティス・ファーマスーティカルズ・インコーポレイテッド ２，６−ジ−ｔ−ブチル−４−［（ジメチル−４−メトキシフェニルシリル）メチルオキシ］フェノール及び２，６−ジ−ｔ−ブチル−４−［（ジメチル−２−メトキシフェニルシリル）メチルオキシ］フェノール
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
JP2002529740A (ja) * 1998-11-09 2002-09-10 アセロジエニクス・インコーポレイテツド 血漿コレステロールレベルを低下させるための方法及び組成物
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
AU2002363318B2 (en) * 2001-10-25 2008-09-11 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EP1451138A4 (en) * 2001-11-09 2005-06-15 Atherogenics Inc METHOD FOR REVERTING AND PREVENTING THE PROCESS OF CARDIOVASCULAR DISEASES
EP1465854A4 (en) * 2001-12-19 2005-06-08 Atherogenics Inc CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
AU2003253887A1 (en) * 2002-07-12 2004-02-02 Atherogenics, Inc. Novel salt forms of poorly soluble probucol esters and ethers
AU2003266165A1 (en) * 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
CN100548950C (zh) * 2003-01-13 2009-10-14 阿特罗吉尼克斯公司 制备普罗布考及其衍生物的酯和醚的方法
US7173129B2 (en) * 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
EP1677804A1 (en) * 2003-10-17 2006-07-12 Amylin Pharmaceuticals, Inc. Silyl phenols for promoting vascular health
US7294737B2 (en) 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
US7271274B2 (en) 2004-04-20 2007-09-18 Ahterogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
AU2005262390B2 (en) * 2004-07-01 2011-09-22 Atherogenics, Inc. Compounds and methods for treating diabetic vascular diseases
WO2008118948A1 (en) * 2007-03-26 2008-10-02 Atherogenics, Inc. Methods and compositions of derivatives of probucol for the treatment of diabetes
WO2008118946A1 (en) * 2007-03-27 2008-10-02 Atherogenics, Inc. Methods and compositions using certain phenolic derivatives for the treatment of diabetes
JP5778755B2 (ja) * 2010-04-15 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドロキノンの製造方法
JP6447858B2 (ja) * 2016-07-08 2019-01-09 Ｙａｎｃｈｅｒｓ株式会社 固形癌治療剤

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129262A (en) * 1962-10-08 1964-04-14 Consolidation Coal Co Reduction of organic thiocyanates
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
US3897500A (en) * 1971-12-10 1975-07-29 Continental Oil Co Alkylidenedithiobisphenols
US3786100A (en) * 1971-12-10 1974-01-15 Continental Oil Co Keto substituted alkylidenedithiobisphenols
JPS61263988A (ja) * 1985-05-16 1986-11-21 Shionogi & Co Ltd シリル置換エ−テル類および殺虫・殺ダニ剤
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US4719237A (en) * 1986-01-28 1988-01-12 Merrell Dow Pharmaceuticals Inc. Cardiac antiarrythmic method employing probucol
US4734527A (en) * 1986-10-17 1988-03-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol
US4772363A (en) * 1987-01-14 1988-09-20 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol by electrocatalysis
US4861443A (en) * 1987-01-14 1989-08-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) by electrocatalysis
US5401883A (en) * 1987-01-20 1995-03-28 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol and 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol)
US4975467A (en) * 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
JPH0813824B2 (ja) * 1988-10-27 1996-02-14 北興化学工業株式会社 有機ケイ素化合物
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US5047555A (en) * 1988-12-13 1991-09-10 Tanabe Seiyaku Co., Ltd. 4-aminophenol derivatives and processes for preparing the same
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5008421A (en) * 1989-07-05 1991-04-16 Aristech Chemical Corporation Silyl derivatives of 2,6-dimethyl-4-allyl phenol
DE3935638A1 (de) * 1989-10-26 1991-05-02 Consortium Elektrochem Ind Organosilylalkylaromaten
US5112870A (en) * 1990-05-09 1992-05-12 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5061734A (en) * 1990-05-09 1991-10-29 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
JP2899064B2 (ja) * 1990-05-23 1999-06-02 キヤノン株式会社 液晶性化合物、これを含む液晶組成物およびこれを使用した液晶素子
US5304668A (en) * 1990-07-05 1994-04-19 Merrell Dow Pharmaceuticals Bis-[4-(2,6-di-alkyl)phenolisilane derivatives as antiatherosclerotic agents
NZ238807A (en) * 1990-07-05 1994-03-25 Merrell Dow Pharma Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5254549A (en) * 1991-12-19 1993-10-19 Merz & Co. Gmbh & Co. New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
HUT69922A (en) * 1992-09-02 1995-09-28 Isis Pharmaceuticals Inc Oligonucleotide modification of cell adhesion
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
WO1994011027A1 (en) * 1992-11-13 1994-05-26 Board Of Regents Of University Of Washington Peripheralization of hematopoietic stem cells
JPH08504792A (ja) * 1992-12-22 1996-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー カルシウムチャンネルアンタゴニストとしてのピペリジン誘導体
EP0678122B1 (en) * 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
WO1995004749A1 (en) * 1993-08-05 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating metabolic function
JP3650144B2 (ja) * 1994-06-08 2005-05-18 花王株式会社 細胞接着抑制剤

Also Published As

Publication number Publication date
CN1216993A (zh) 1999-05-19
PT900225E (pt) 2002-06-28
EP0900225A1 (en) 1999-03-10
JP2001509782A (ja) 2001-07-24
DK0900225T3 (da) 2002-05-13
IL126758A0 (en) 1999-08-17
EP0900225B1 (en) 2002-01-30
BR9709190A (pt) 1999-08-10
ZA973503B (en) 1997-10-30
KR20000065101A (ko) 2000-11-06
KR100503181B1 (ko) 2006-03-03
CA2251991A1 (en) 1997-11-06
ES2167716T3 (es) 2002-05-16
TW474940B (en) 2002-02-01
DE69710191T2 (de) 2002-07-25
DE69710191D1 (de) 2002-03-14
CA2251991C (en) 2002-05-14
ATE212639T1 (de) 2002-02-15
JP4309473B2 (ja) 2009-08-05
NO985039L (no) 1998-12-21
WO1997041129A1 (en) 1997-11-06
NO985039D0 (no) 1998-10-29
AU1985497A (en) 1997-11-19
AU711322B2 (en) 1999-10-14
US5608095A (en) 1997-03-04

Similar Documents

Publication Publication Date Title
AR006890A1 (es) Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos
IL117805A0 (en) Carbonyl piperazinyl and piperidinyl compounds
CO4810230A1 (es) Nuevos derivados del 19-nor-pregneno
AR012032A1 (es) Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
MX9304587A (es) Derivados de 4-aza-5alfa-androstan-3-ona sustituidos en la posicion 17-beta, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
SE8500877D0 (sv) Nya enkafalinderivat
EA200100983A1 (ru) Производные 13-метилэритромицина
MY107001A (en) Pharmaceutical compounds.
DK0984942T3 (da) Flydende benz-iso-quinolinderivater
DE69206274T2 (de) 3-ureido-benzodiazepinone verwendbar als cck- oder gastrin-antagonisten.
AU5551594A (en) Substituted amino alkyl compounds
DK1468692T3 (da) Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom
ES520860A0 (es) Procedimiento de preparar teofilinas 7-substituidas.
AR006891A1 (es) Metodo de inhibicion de la molecula-1de adhesion celular vascular y tratamiento de enfermedades cronicas con 2,6-dialquil-4-sililfenoles
TW334425B (en) Annelated dihydropyridines for preparing pharmaceutical preparations
TR199802163T2 (xx) 4'-Triflorometilbifenil-2-karboksilik asit
CO5160255A1 (es) DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO[4,5-b]INDOL-1- CARBOXAMIDA Y COMPOSICIONES QUE LOS COMPRENDEN
CO5180536A1 (es) Inhibidores de proteasas catepsina
FI891087A (fi) Nya kefemfoereningar och foerfarande foer deras framstaellning.
ES2117003T3 (es) Derivados oligopeptidicos de hipoxantina dotados de actividad inmunomoduladora, y composiciones farmaceuticas que los contienen.
FI875583A0 (fi) Nya kondenserade diazepinoner, foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel.
AR247737A1 (es) Un procedimiento para la fabricacion de compuestos.
FI971177A0 (fi) Bisyklisiä karboksiamideja 5-HT1A-antagonisteina
DE60008362D1 (en) 3-bicycloaryl-2-aminomethyl bicycloalkane als serotoniner reuptake inhibitor